# Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes

> **NCT03396484** · PHASE2 · WITHDRAWN · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)**

## Conditions studied

- Type1 Diabetes Mellitus

## Interventions

- **DRUG:** Methyldopa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03396484
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09
- **Primary completion:** 2022-03
- **Final completion:** 2022-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study not begun due to continued laboratory work on the feasibility of outcome measures.
- **Last updated:** 2020-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03396484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03396484, "Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03396484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*